Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
197
datasets available to search
ShareScore release 0.7.1
Dataset results
197 results for “BCMA”
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
ClinicalTrials.gov study NCT07249073. IPD Sharing: Not stated. Countries: 1. Publications: 0.
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
ClinicalTrials.gov study NCT04271644. IPD Sharing: NO. Countries: 1. Publications: 0.
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT05722418. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
ClinicalTrials.gov study NCT06759181. IPD Sharing: NO. Countries: 1. Publications: 0.
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
ClinicalTrials.gov study NCT04776330. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
ClinicalTrials.gov study NCT07152223. IPD Sharing: NO. Countries: 1. Publications: 0.
BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma
ClinicalTrials.gov study NCT04236011. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT07340853. IPD Sharing: NO. Countries: 1. Publications: 0.
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
ClinicalTrials.gov study NCT05981209. IPD Sharing: NO. Countries: 1. Publications: 0.
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT06644443. IPD Sharing: NO. Countries: 1. Publications: 0.
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
ClinicalTrials.gov study NCT07009899. IPD Sharing: NO. Countries: 1. Publications: 0.
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
ClinicalTrials.gov study NCT07339540. IPD Sharing: Not stated. Countries: 1. Publications: 0.
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
ClinicalTrials.gov study NCT05846737. IPD Sharing: NO. Countries: 1. Publications: 0.
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
ClinicalTrials.gov study NCT06941129. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT05000450. IPD Sharing: Not stated. Countries: 1. Publications: 0.
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
ClinicalTrials.gov study NCT06947460. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor
ClinicalTrials.gov study NCT04650724. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
ClinicalTrials.gov study NCT06594211. IPD Sharing: Not stated. Countries: 1. Publications: 0.
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03943472. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03486067. IPD Sharing: Not stated. Countries: 6. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.